Rybelsus is the historical U.S. oral semaglutide diabetes brand whose wholesale supply was phased out during 2026 as Novo Nordisk launched its updated tablet formulation under the Ozempic name. The history has three separate regulatory or commercial milestones: FDA approved the newer R2 oral semaglutide formulation in December 2024, FDA approved its Ozempic naming supplement on January 30, 2026, and the manufacturer began the U.S. Ozempic tablet rollout in May 2026. A historical Rybelsus entry in an insurer portal or pharmacy catalog is not proof of current stock.
The older Rybelsus tablets were marketed in 3 mg, 7 mg and 14 mg strengths. Ozempic tablets use 1.5 mg, 4 mg and 9 mg strengths and an updated formulation with different bioavailability. The two tablet families contain semaglutide but should not be converted milligram for milligram by a patient or retailer. NovoCare patient instructions say a new prescription is required when moving from Rybelsus to Ozempic tablets.
This page is a documented product-transition guide, not a Rybelsus checkout page or current price feed. It explains the 2026 supply transition and practical questions to ask the clinician and pharmacist. For current tablet product identity see Ozempic pill, while the prescription renewal guide covers the separate clinical authorization step.
An Illinois Medicaid provider notice dated May 21, 2026 reported Novo Nordisk’s decision to stop U.S. wholesaler shipments of all Rybelsus strengths beginning in May, with remaining inventory expected to become limited starting in July. The manufacturer’s patient materials likewise describe the U.S. transition to Ozempic tablets. These are supply-chain statements, not an assertion that every pharmacy had zero remaining packages on the same date.
Rybelsus may remain authorized or marketed in other countries, but foreign availability cannot be substituted for legitimate U.S. prescription supply. Avoid interpreting an international seller’s listing or an outdated price result as an approved domestic purchase route.
Rybelsus R1 tablets used 3 mg, 7 mg and 14 mg strengths. The R2 oral semaglutide formulation was approved by FDA on December 9, 2024, with improved bioavailability and lower numbered strengths of 1.5 mg, 4 mg and 9 mg. The FDA reviewed the R2 formulation and later approved the branding change to Ozempic tablets on January 30, 2026; the new brand rollout is a different event from the original R2 formulation approval.
The FDA review describes corresponding R1/R2 strengths within that specific approval, but this history is not permission for patients to perform their own conversions or a pharmacy to interpret an old prescription as an Ozempic order without proper authorization. The comparison matrix identifies which product a clinician and pharmacist should reconcile, not a personal switching schedule.
| Legacy product | Newer U.S. product | Why the distinction matters | Follow-up |
|---|---|---|---|
| Rybelsus tablet 3 mg | Ozempic tablet 1.5 mg | Different strength and formulation, not a self-directed equivalence | Clinician-issued new Rx |
| Rybelsus tablet 7 mg | Ozempic tablet 4 mg | New packaging and label identity | Confirm new order with pharmacy |
| Rybelsus tablet 14 mg | Ozempic tablet 9 mg | Different numeric strength; supervised transition | Use current product instructions |
| Rybelsus historical brand | Ozempic current oral product | U.S. wholesale phase-out vs active product channel | Ozempic pill details |
A pharmacy cannot simply reinterpret an old Rybelsus order as permission to supply a newly labeled Ozempic tablet strength. The prescriber should decide whether the new formulation is appropriate, review the patient’s current therapy and specify the new product correctly. The manufacturer explicitly advises patients that moving to Ozempic pill needs a new prescription.
Patients should verify the new prescription name, strength, instructions and quantity with both clinician and pharmacist. Avoid using an online strength conversion table to make this decision. The online prescription guide describes access to a clinical assessment where appropriate.
Legacy Rybelsus labeling and newer Ozempic oral labeling address type 2 diabetes care in adults. Manufacturer transition materials also discuss the tablets’ roles in reduction of major cardiovascular events for eligible high-risk adults with type 2 diabetes. Do not infer that Rybelsus was the FDA-approved Wegovy weight-management pill.
The current oral Ozempic indication should be checked independently of Ozempic injection indications: the latter includes certain additional product-specific contexts. The Ozempic brand guide explains why all semaglutide labels are not identical.
A retailer may have historic catalog entries, payer data or occasional leftover inventory, but those facts alone do not establish a reliable future supply. Ask the actual licensed pharmacy to verify the product’s legal availability, expiration, source and whether it can lawfully fill the particular prescription. This page does not claim any pharmacy currently holds Rybelsus.
Be cautious of promotions exploiting the phase-out with claims of unlimited Rybelsus supply, no prescription, overseas direct shipping or improbable pricing. The online pharmacy verification guide provides U.S. licensing warning signs.
A medication name change can require a pharmacy claim with a different product identifier or a revised prescription record. Manufacturer FAQs describe continuation of certain existing Rybelsus savings offers for Ozempic tablets, but actual coverage and patient cost still depend on plan rules and program conditions. Do not generalize the manufacturer statement into universal insurer acceptance.
Confirm the current tablet product, plan formulary entry, authorized pharmacy and patient-specific amount. Read Ozempic coverage for payer mechanics, not as evidence that legacy Rybelsus can still be purchased routinely.
Prepare the old product name and strength, the timing of the current prescription, any remaining supply, other medicines, treatment updates and your pharmacy information. Contact the original prescribing team about the new Ozempic tablet prescription and whether additional review is needed. Then ask the pharmacist to identify the new labeled medicine and explain its instructions.
Do not stop, overlap, double up or change oral semaglutide on your own. If there is an interruption in access, the prescriber should advise what is appropriate. This page is intended to support a safer handoff, not suggest an individualized switching timetable.
Oral semaglutide has special absorption considerations, so the pharmacist should explain the new product-specific administration instructions rather than assuming a person remembers every detail from a legacy bottle. Tablets and injection pens are also very different routes of administration even where they share the Ozempic brand.
For updated tablet packaging, strengths and how the prescription differs from injection, consult the oral Ozempic product guide and tablet versus pen choices.
Semaglutide medicines carry important FDA warnings, including a boxed thyroid C-cell tumor warning and contraindications involving medullary thyroid carcinoma or MEN 2. Clinicians should also review relevant gastrointestinal, gallbladder, pancreatic, kidney, retinopathy and interacting-medication concerns as applicable.
A product transition is a reason to check the medication list and clinical status, not a substitute for medical care. Seek prompt clinical guidance for worrying symptoms rather than interpreting this product history as personalized safety clearance.
Novo Nordisk’s announced transition concerns U.S. marketing and wholesale supply. Rybelsus may have a distinct status in other jurisdictions. Global catalog pages and international approvals do not override the U.S. FDA product identification, import and pharmacy dispensing requirements applicable to a U.S. patient.
A foreign package bearing the familiar brand is not proof of legitimate U.S. supply. Review the imported semaglutide guide if you encounter cross-border offers.
A precise chronology prevents two approval dates from being conflated. September 2019: the original Rybelsus R1 tablet brand was FDA-approved. December 9, 2024: FDA approved the more bioavailable R2 formulation at 1.5, 4 and 9 mg. January 30, 2026: the FDA supplement changed the R2 product’s branded name to Ozempic tablets. May 2026: the manufacturer introduced the newly named product in U.S. supply channels and ended routine Rybelsus wholesaler shipments. These milestones concern FDA filings and a national launch, not each store’s inventory.
A May 21, 2026 Illinois Medicaid provider notice describes the wholesaler cutoff and expectations of diminishing Rybelsus inventory in subsequent months. When looking at a live pharmacy listing in October 2026, the critical question remains whether an authorized dispenser can verify lawful usable supply for the exact prescription; a permanent website listing alone is inconclusive.
Ask the pharmacy whether the entry is a historical catalog listing or actual lawful stock, and whether the prescriber has issued the new Ozempic tablet prescription. Confirm the labeled formulation and numeric strength on the new order. A staff member may need to coordinate with the prescriber or payer when the old and new product identifiers differ.
Do not ask staff to substitute strengths using a conversion chart you found online. A good outcome is a verified product-specific prescription and a clear explanation of the current U.S. formulation, even if that requires another clinician contact before dispensing.
This guide reflects NovoCare transition information and the May 2026 Illinois provider notice, reviewed on October 18, 2026. It deliberately omits current Rybelsus buy links, claimed stock and live price quotations because routine wholesale supply has been phased out.
Some outbound commercial links may be affiliate or sponsored referrals, meaning this independent information site may receive compensation if readers use them. Commercial relationships do not establish product suitability, pharmacy licensing or prescription eligibility; any compensation is identified alongside the relevant outbound link.
Novo Nordisk informed a state payer that U.S. Rybelsus wholesale shipments would cease starting in May 2026 as Ozempic tablets replaced it. Residual pharmacy inventory cannot be assumed.
No. Ending wholesale shipments and the disappearance of all remaining stock are different events. Individual lawful pharmacy supply needs direct confirmation.
A newer oral semaglutide formulation marketed as Ozempic tablets in 1.5 mg, 4 mg and 9 mg strengths.
No. The formulations and labeled numeric strengths differ. A clinician must issue an appropriate new prescription and explain the product instructions.
Yes. Manufacturer patient transition guidance explicitly advises getting a new Ozempic tablet prescription.
No. They share semaglutide but have different branding, products, strengths and FDA-labeled clinical purposes.
No. This page discusses the U.S. wholesale phase-out; other jurisdictions can have different brand marketing status.
Coverage depends on the current plan and product claim. Manufacturer materials describe transition support, but no individual payment amount or approval is guaranteed.
Do not assume overseas Rybelsus listings represent approved lawful U.S. supply. Consult a U.S.-licensed pharmacy and prescriber about the FDA-approved replacement route.